In this article, we will analyze the Valiant Laboratories share price target for 2023, 2024, 2025, 2030, and 2035 based on the company’s financials and various reports from brokerage firms.
The pharmaceutical API industry in India is ranked third globally in terms of volume. It is expected to clock a CAGR of 5-7% between fiscal 2023 and 2027.
Paracetamol is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy for pain conditions by the World Health Organization (WHO).
Recent News-
Valiant laboratories are listed on BSE and NSE at a price of Rs 162.10 against the issue price of Rs 140, with a premium of 15%.
The IPO issue was for Rs. 152.46 crore.
IPO is an entirely fresh issue of total Rs 152.46 crore.
Objective of the IPO:
- General Corporate Purposes
- Investment in Valiant Advanced Sciences Private Limited (VASPL)
Financial Report-
The company has sustained revenue growth, growing at a CAGR of 35.35 during FY21–23.
Company overview-
Valiant Laboratories Limited was founded in 1980 and has a strong reputation for quality and compliance, with a focus on R&D and continuous process improvement.
Valiant Laboratories is a company engaged in the production of paracetamol, active pharmaceutical ingredients (API), and bulk drug manufacturing. Valiant Laboratories produces paracetamol in various grades like IP, BP, EP, and USP. All products are manufactured to meet the specific requirements of their customers as per pharmacopeia standards.
Valiant laboratories strategically position its manufacturing plants, located around 150 KM away from JNPT Port in Navi Mumbai, Maharashtra. The company imports raw materials for their products from China and Cambodia. The company is trying to reduce its dependency on external suppliers and procures this raw material through its promoter group company, Valiant Organics Limited.
Subsidiary Companies-
- Valiant Organics Limited
- Valiant Advanced Sciences Private Limited
Fundamentals-
| Market Cap | 760 Cr |
| P/E Ratio | 68.34 |
| Industry P/E | 36.20 |
| Debt to Equity | 0.58 |
| Return on Equity | 21.12% |
| Dividend Yield | 0.00% |
Net-profit margin-
| Year | Revenue | Profit |
|---|---|---|
| 2023 | 334 | 29 |
| 2022 | 292 | 28 |
| 2021 | 182 | 31 |
Share-Holding pattern
| Dec’23 | Sep’23 | |
|---|---|---|
| Promoters | 74.94% | 74.94% |
| Retail | 17.96% | 16.38% |
| Foreign Institutions | 7.08% | 8.64% |
| Domestic Institutions | 0.02% | 0.04% |
Share price targets for a specific company are highly speculative and influenced by numerous factors, such as market conditions, economic indicators, company performance, industry trends, and many more.
We will predict the Valiant Laboratories share price target in 2023, 2024, 2025, 2030, and 2035 by analyzing the previous performance and after studying various brokerage and research firm forecasts.
Valiant Laboratories share price target: 2023
| 2023 | Minimum Share Price | Maximum Share price |
|---|---|---|
| November | 148 | 211 |
| December | 165 | 219 |
The share price of Valiant Laboratories is expected to continue experiencing volatility throughout the year, with a maximum price target of Rs 219 in December 2023 and a minimum price target of Rs 148 in November 2023. The average price target for Valiant Laboratories in 2023 is expected to be around Rs 185.
Valiant Laboratories share price target prediction for 2023 is based on the company’s financials, previous trends, and various brokerage firm reports.
Valiant Laboratories share price target: 2024
The share price of Valiant Laboratories is expected to continue experiencing volatility throughout the year, with a maximum price target of Rs 335 in December 2024 and a minimum price target of Rs 172 in February 2024. The average price target for Valiant Laboratories in 2024 is expected to be around Rs 288.
Valiant Laboratories Share’s price target prediction for 2024 is based on the company’s financials, previous trends, and various brokerage firm reports.
Valiant Laboratories share price target: 2025
The share price of Valiant Laboratories is expected to continue experiencing volatility throughout the year, with a maximum price target of Rs 485 in December 2025 and a minimum price target of Rs 335 in March 2025. The average price target for Valiant Laboratories in 2025 is expected to be around Rs 420.
Valiant Laboratories share price target prediction for 2025 is based on the company’s financials, previous trends, and various brokerage firm reports.
Valiant Laboratories share price target: 2030
The share price of Valiant Laboratories is expected to continue experiencing volatility throughout the year, with a maximum price target of Rs 1065 in December 2030 and a minimum price target of Rs 846 in March 2030. The average price target for Valiant Laboratories in 2030 is expected to be around Rs 956.
Valiant Laboratories Share’s price target prediction for 2030 is based on the company’s financials, previous trends, and various brokerage firm reports.
Valiant Laboratories share price target: 2035
The share price of Valiant Laboratories is expected to continue experiencing volatility throughout the year, with a maximum price target of Rs 2548 in December 2035 and a minimum price target of Rs 2264 in March 2035. The average price target for Valiant Laboratories in 2035 is expected to be around Rs 2385.
Valiant Laboratories Share’s price target prediction for 2035 is based on the company’s financials, previous trends, and various brokerage firm reports.
Strength of Valiant Laboratories
The company experienced a consistent increase in revenue from operations, with a compounded annual growth rate (CAGR) of 23.90%.
The company’s quality control team monitors the manufacturing process at all stages, from the initial testing stage for incoming raw materials to the final product before packaging.
Weaknesses of Valiant Laboratories
Valiant Laboratories operates solely from a single manufacturing unit situated in Palghar, Maharashtra. Any localized social unrest, natural disasters, service breakdowns, or disruptions in production at this facility could significantly harm the company’s business and financial condition.
The company relies on a limited number of suppliers for its raw materials, primarily concentrated in the western region of India.
The company’s revenue is heavily dependent on a small number of customers, which could negatively affect the business and operational health.
Conclusion
The company is dependent on sales of a single product (paracetamol) for its revenue. Any changes to the paracetamol API industry or product demand will adversely affect its business.
Valiant Laboratories made a good debut on the BSE and NSE and hit the upper circuit on its debut day.
Valiant Laboratories share price targets for 2023, 2024, 2025, 2030, and 2035 are discussed above.
Disclaimer: I am not a SEBI-registered investment adviser or research analyst. The information shared is only for educational purposes. This is not an investment advice.